Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.
Shares of Flexion Therapeutics soared in trading on Oct. 11 after Pacira Biosciences announced the acquisition of the Burlington, Massachusetts-based biopharmaceutical company for $427 million in cash.
Boston Scientific entered into a deal to acquire Baylis Medical, a medical devices maker with headquarters in Canada, for an upfront payment of $1.75 billion in a bid to expand the Mass.-based company’s electrophysiology and structural heart product portfolio.
Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company.
Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
Novartis is expanding the Swiss pharma giant’s optogenetics portfolio with the acquisition of gene therapy company Arctos Medical.
According to a California WARN notice, Sanofi is shuttering Principia Biopharma’s laboratories in San Francisco and laying off about three dozen employees after the Phase III PEGASUS trial failure of rilzabrutinib for pemphigus.
Fully integrated biopharmaceutical solutions organization Syneos Health announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company.
Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.
Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest.
